

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Dillon

) Art Unit: 3627

) Examiner: Unknown

) 16698,11.18

Serial No: 10/578,037

Filed: May 2, 2006

For: AUTHENTICATION AND TRACKING SYSTEM

To: Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This communication is being transmitted along with this Disclosure Statement to incorporate that US Pub. No. 2003/0141358, having been previously disclosed by Applicant via Information Disclosure Statement filed on December 1, 2006, claims priority to PCT No. PCT/GB01/02480, published as Pub. No. WO/0195249. PCT/GB01/02480 is the parent of the following three filed Great Britain patent applications:

- (i) application no. GB001366A0, filed June 5, 2000;
- (ii) application no. GB0015091A0, filed June 20, 2000; and
- (iii) application no. GB0019258A0, filed August 4, 2000.

The above Great Britain patent applications are not available for citing in this Supplemental Information Disclosure Statement as they were withdrawn before being published. Therefore, we have only cited WO/0195249 herein.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.K./

Receipt date: 12/21/2006

Respectfully submitted,

/John S. Parzych/

Dated: December 21, 2006

John S. Parzych  
Reg. No. 52,097  
FREDRIKSON & BYRON, P.A.  
(Customer No. 022859)  
200 South Sixth Street, Suite 4000  
Minneapolis, MN 55402-1425  
(612) 492-7279

4127554\_1.DOC

Receipt date: 12/21/2006

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10701377	
	Filing Date		2003-11-03	
	First Named Inventor	David G. Dillon		
	Art Unit	3627		
	Examiner Name	Gerald J. O'Connor		
	Attorney Docket Number	16698.11.1		

#### U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

#### U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

#### FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	WO/0195249	GB		2001-12-13	OP-TAGLIO LIMITED		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

#### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>

Receipt date: 12/21/2006

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10701377
	Filing Date	2003-11-03
	First Named Inventor	David G. Dillon
	Art Unit	3627
	Examiner Name	Gerald J. O'Connor
	Attorney Docket Number	16698.11.1

1	World Health Organization. Substandard and counterfeit medicines. [retrieved on 2006-12-15] retrieved from the internet <a href="http://www.who.int/mediacentre/factsheets/2003/fs275/en/print.html">http://www.who.int/mediacentre/factsheets/2003/fs275/en/print.html</a>	<input type="checkbox"/>
2	HOPKINS, DM, KONTRIK, LT, and TURNAGE, MT. Counterfeiting Exposed; Protecting Your Brand and Customers, Chapter 12, "Anticounterfeiting Technology Solutions," pp 249-262	<input type="checkbox"/>
3	JOHNSTON, RG. Tamper detection for safeguards and treaty monitoring: fantasies, realities, and potentials. Nonproliferation Review 2001 Spring; 8 (1); 102-115	<input type="checkbox"/>
4	JOHNSTON, RG and GARCIA, ARE. An annotated taxonomy of tag and seal vulnerabilities. Journal of Nuclear Materials Management 2000 Spring; 229 (3); 23-30	<input type="checkbox"/>
5	JOHNSTON, RG. Tamper-indicating seals for nuclear disarmament and hazardous waste management. Science and Global Security 2001; 9 (2); 93-112	<input type="checkbox"/>
6	JOHNSTON, RG, GARCIA, ARE, and PACHECO, AN. Efficacy of tamper-indicating devices. Journal of Homeland Security 2002, April 16	<input type="checkbox"/>
7	JOHNSTON, RG and GARCIA, ARE. Analyzing vulnerability results for tag and tamper-indicating seals. Proceedings of the U.S. Army Conference on Applied Statistics; 2001 October 24-26; Santa Fe, NM. pp. 60-88	<input type="checkbox"/>
8	KARSTEN, R. Tags tag counterfeits: as counterfeiting methods become increasingly sophisticated, more advanced technologies are needed to fight back. Manufacturing Chemist 2003 January 1; 73 (1) [retrieved 2006-11-30] retrieved from the internet <a href="http://www.manufacturing-chemist.info/story.asp?storyCode=15146">http://www.manufacturing-chemist.info/story.asp?storyCode=15146</a>	<input type="checkbox"/>
9	KONTRIK, L. Counterfeits: the cost of combat. Pharmaceutical Executive 2003 November 1 [retrieved 2006-12-15] retrieved from the internet <a href="http://www.pharmexec.com/pharmexec/content/printContentPopup.jsp?id=75674">http://www.pharmexec.com/pharmexec/content/printContentPopup.jsp?id=75674</a>	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Jamie Kucab/	Date Considered	04/30/2010
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Receipt date: 12/21/2006

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10701377
	Filing Date	2003-11-03
	First Named Inventor	David G. Dillon
	Art Unit	3627
	Examiner Name	Gerald J. O'Connor
	Attorney Docket Number	16698.11.1

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

Receipt date: 12/21/2006

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10701377
	Filing Date	2003-11-03
	First Named Inventor	David G. Dillon
	Art Unit	3627
	Examiner Name	Gerald J. O'Connor
	Attorney Docket Number	16698.11.1

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/John S. Parzych/	Date (YYYY-MM-DD)	2006-12-21
Name/Print	John S. Parzych	Registration Number	52097

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.